

**AGREEMENT UPLOAD & GENERAL INFORMATION**

**University of Rochester**

PI:

Agreement Creator/Primary Contact:

Agreement Type (CDA/DUA/MTA/OUA):

Responsible department/division\*:

*\*This defaults to the PI's primary department can be updated if necessary*

Agreement Collaborators (any UR staff given read/edit permissions):

**Contracting Party (External entity)**

Organization/Entity:

Organization's Contact (ORPA Equivalent) Name and Email:

Scientist Name:

Scientist Email:

Agreement Draft: First draft to be generated internally?: Yes  No  \*If no, attach agreement draft.

Project/Study Title (ex. PI last name-MTA-contracting party-date OR material name):

Are all contracting parties for this agreement based in the United States?: Yes  No

→ If no, list countries:

**DIRECTION OF TRANSFER:** Incoming  Outgoing  Both

**MATERIAL INFORMATION (Required information is determined by direction of transfer)**

Are you exporting Material outside the United States?: Yes  No

For institutionally developed technology, are there transfer costs that should be reimbursed to your lab?

Yes  No

**Conflict of Interest:** Do you have a financial relationship with the Data Recipient (for example, consulting income or stock) and/or have you received, or will you receive, a financial gift from the Data Recipient?: Yes  No

→ If yes, please provide details:

**MATERIAL DESCRIPTION**

Identify the material [Provide exactly how the material should be specified in the MTA]:

List the quantity of the material to be transferred (specify units):

What is the origin of the material? Human  Plasmid  Animal  Plant  Other:

Are you sending/receiving live animals?

Yes  No

Does the material require:

(\*Responding "yes" to any of the below will result in additional review by biosafety)

- a. An import permit? (see [Shipping Procedure](#))  
Yes  No
- b. An export license if sending out of the U.S.? (Submit export compliance questions to [export@rochester.edu](mailto:export@rochester.edu)) (Please consult this [link](#) to see if the material is covered by ECCN 1C351, 1C353, or 1C354)?  
Yes  No
- c. Institutional Biosafety Committee Approval (BSL2, nucleic acids from BSL3 or BSL4 agents)? (See [here](#))  
Yes  No
- d. Due diligence / restricted quantities (I.e., permissible [amounts](#) of Select Toxins)  
Yes  No

**HUMAN MATERIAL DESCRIPTION (REQUIRED ONLY FOR HUMAN SUBJECT MATERIALS)**

IRB protocol number (or exemption number):

Is the Material de-identified [all HIPAA identifiers removed]?

Yes  No

## MATERIAL SOURCE AND DEVELOPMENT

Did the material originate at the University of Rochester?

Yes  No  Both, UR material incorporated with material received from a third party

Describe your institution's original material, its relationship to the third-party material, and how the materials have been combined:

Was development of this material funded by a sponsored research agreement or other extramural funding?

Yes  No

## MATERIAL USE

Provide a concise scientific description of the researcher's use of this material:

## MTA ADDITIONAL INFORMATION

Add any comments that will be helpful to the ORPA staff: